Abstract
Background: Uncertainties remain regarding the nature and durability of the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Aim: This study investigated immunoglobulin G response and neutralizing activity to evaluate the mean antibody concentrations and response duration induced by each vaccination regimen in a French adult population. Methods: A study including blood sampling and questionnaires was carried out from November 2020 to July 2021 with three separate follow-up phases. Spike proteins and neutralizing antibodies were quantified using ELISA and a virus-neutralization test. Results: Overall, 295 participants were included. Seroprevalences were 11.5% (n = 34), 10.5% (n = 31), and 68.1% (n = 201) in phases 1, 2, and 3, respectively. Importantly, 5.8% (n = 17) of participants lost their natural antibodies. Antibody response of participants with only a prior infection was 88.2 BAU/mL, significantly lower than those vaccinated, which was 1909.3 BAU/mL (p = 0.04). Moreover, the antibody response of vaccinated participants with a prior infection was higher (3593.8 BAU/mL) than those vaccinated without prior infection (3402.9 BAU/mL) (p = 0.78). Vaccinated participants with or without prior infection had a higher seroneutralization rate (91.0%) than those unvaccinated with prior infection (65.0%). Conclusion: These results demonstrated that single infection does not confer effective protection against SARS-CoV-2.
Funder
European Commission
Aix-Marseille University
Institut national de la santé et de la recherche médicale
University of Corsica
Subject
Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health
Reference39 articles.
1. Identification of a Novel Coronavirus Causing Severe Pneumonia in Human: A Descriptive Study;Chin. Med. J.,2020
2. Ministère des Solidarités et de la Santé (2022, October 25). Le Calendrier de la Campagne Vaccinale Contre la COVID-19. Available online: https://solidarites-sante.gouv.fr/archives/archives-presse/archives-communiques-de-presse/article/vaccination-contre-la-covid-en-france-au-26-novembre-2021-pres-de-104-413-200.
3. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19);Clin. Infect. Dis.,2020
4. Robust Neutralizing Antibodies to SARS-CoV-2 Infection Persist for Months;Science,2020
5. Evidence for Antibody as a Protective Correlate for COVID-19 Vaccines;Vaccine,2021